A United Kingdom Conformity Assessed marking was granted to the Avantect Multi-Cancer Detection Test and Avantect Ovarian Cancer Test.

ClearNote Health's Avantect® Pancreatic Cancer Test will be used in a landmark study of pancreatic cancer detection in high-risk patient population

ClearNote Health will present performance data for its Avantect Pancreatic Cancer Test at the Digestive Disease Week 2026 conference.

Archerfish is working to build awareness and provide access to Clearnote's Avantect early cancer detection platform for pancreatic and ovarian cancer screening.

Reviewers winnowed an initial 27 assays to a group of nine that were evaluated using NCI sample sets, ultimately choosing ClearNote's Avantect and Guardant's Shield.

ClearNote Health has secured the UK Conformity Assessed (UKCA) marking for the company's Avantect Pancreatic Cancer Test.

SAN DIEGO, July 09, 2025--ClearNote Health has received UK Conformity Assessed marking for its Avantect® Pancreatic Cancer Test.

SAN DIEGO, July 09, 2025--ClearNote Health has received UK Conformity Assessed marking for its Avantect® Pancreatic Cancer Test.

ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced an agreement with Claritev, Inc. (“Claritev”) (NYSE: CTEV), previously MultiPlan, In...

ClearNote Health and the University of Southampton's Clinical Trials Unit are to use the Avantect Pancreatic Cancer Test in a study.

BCAL Diagnostics (ASX: BDX) is on track to launch the cutting-edge Avantect pancreatic and ovarian cancer tests onto the Australian market in the new year.

SAN DIEGO--(BUSINESS WIRE)--#5hmC--ClearNote Health, a company dedicated to improving early detection for some of the deadliest cancers, today announced it will present new multi-cohort validation data for its Avantect® Pancreatic Cancer Test at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 29 – June 2. ASCO attendees are invited to meet with ClearNote Health’s scientific and medical leadership team, including newly appointed Chief Medical Officer Jeffrey Venstrom, MD, and Chief Scientific Officer Samuel Levy, PhD, to discuss the company’s latest clinical data, strategic commercialization progress, and vision for advancing early cancer detection. “Pancreatic cancer remains one of the most lethal malignancies because it is often diagnosed too late for curative intervention,” said Dr. Venstrom. “We are excited to share new validation data at ASCO demonstrating the strong performance of our Avantect Pancreatic Cancer Test among individuals with elevated risk. This test complements existing diagnostic and risk assessment strategies and provides clinically actionable insights when earlier detection can make the greatest difference.” During the 2026 ASCO Annual Meeting, ClearNote Health will present results from an independent validation cohort of 1,445 individuals with multiple risk factors, including type 2 diabetes, family history, and genetic predisposition...